Next Article in Journal
Iodine Status of Women of Reproductive Age in Sierra Leone and Its Association with Household Coverage with Adequately Iodized Salt
Next Article in Special Issue
Nanoscale Delivery of Resveratrol towards Enhancement of Supplements and Nutraceuticals
Previous Article in Journal
Supplementation with Guanidinoacetic Acid in Women with Chronic Fatigue Syndrome
Article Menu

Export Article

Open AccessArticle
Nutrients 2016, 8(2), 73; doi:10.3390/nu8020073

Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors

1
Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, RS, Brazil
2
Postgraduate Program in Medicine: Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil
*
Author to whom correspondence should be addressed.
Received: 27 October 2015 / Revised: 22 December 2015 / Accepted: 20 January 2016 / Published: 29 January 2016
(This article belongs to the Special Issue Selected Papers from Resveratrol Regional Meeting 2015)
View Full-Text   |   Download PDF [406 KB, uploaded 29 January 2016]   |  

Abstract

Background: Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ. Methods and Results: This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%). Conclusion: In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels. View Full-Text
Keywords: cardiovascular disease; cholesterol; resveratrol; schizophrenia cardiovascular disease; cholesterol; resveratrol; schizophrenia
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Zortea, K.; Franco, V.C.; Francesconi, L.P.; Cereser, K.M.M.; Lobato, M.I.R.; Belmonte-de-Abreu, P.S. Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors. Nutrients 2016, 8, 73.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top